This American Academy of Ophthalmology initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for neovascular age-related macular degeneration (nAMD).

This CME-accredited collection features:

  • Expert panel discussions on emerging evidence and therapeutic strategies
  • Real-world patient cases contextualizing clinical trial outcomes

Click on the activities below to explore valuable insights and clinical decision-making around:

  • Therapy selection based on patient characteristics and disease progression
  • Individualized dosing strategies and treatment intervals
  • Monitoring response and adjusting therapy to reduce treatment burden
Translating the Latest Data for More Durable Intravitreal Anti-VEGF Therapies to Treat nAMD in Clinical Practice

Webinar
Credit Hours: 0.50 (30 min)

Safety of the More Durable Anti-VEGF Therapies: Findings From Treatment of nAMD in Clinical Trials and Real-World Practice

Webinar
Credit Hours: 0.50 (30 min)

Case Studies in Personalizing Treatment for nAMD Using More Durable Anti-VEGF Therapies

Webinar
Credit Hours: 0.50 (30 min)

Initiating More Durable Anti-VEGF Therapies in Patients With nAMD

Patient Simulation
Credit Hours: 0.25 (15 min)

Switching to a More Durable Anti-VEGF Agent for nAMD

Patient Simulation
Credit Hours: 0.25 (15 min)

Extending Treatment Durability With
Next-Generation nAMD Therapies

Webinar
Credit Hours: 0.50 (30 min)
This activity has expired and is no longer available for credit